These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19821404)

  • 41. Comment on: Varus malalignment negates the structure-modifying benefits of doxycycline in obese women with knee osteoarthritis.
    Sharma L
    Osteoarthritis Cartilage; 2010 Aug; 18(8):1006-7. PubMed ID: 20493958
    [No Abstract]   [Full Text] [Related]  

  • 42. Joint structure modification in osteoarthritis: development of SMOAD drugs.
    Beary JF
    Curr Rheumatol Rep; 2001 Dec; 3(6):506-12. PubMed ID: 11709113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues.
    Riddle D; Perera R
    Ann Rheum Dis; 2022 Apr; 81(4):e65. PubMed ID: 32321719
    [No Abstract]   [Full Text] [Related]  

  • 44. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2022 Apr; 81(4):e66. PubMed ID: 32424029
    [No Abstract]   [Full Text] [Related]  

  • 45. The effect of doxycycline on canine hip osteoarthritis: design of a 6-months clinical trial.
    Nganvongpanit K; Pothacharoen P; Suwankong N; Ong-Chai S; Kongtawelert P
    J Vet Sci; 2009 Sep; 10(3):239-47. PubMed ID: 19687625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of Doxycycline as an Osteoarthritis Disease-Modifying Drug.
    Shanmugasundaram S; Solanki K; Saseendar S; Chavada VK; D'Ambrosi R
    J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Some disease-modifying osteoarthritis drugs make small improvements in knee and hip osteoarthritis.
    Pisetsky DS
    Ann Intern Med; 2021 Sep; 174(9):JC104. PubMed ID: 34487443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eligibility criteria in knee osteoarthritis clinical trials: systematic review.
    Koog YH; Wi H; Jung WY
    Clin Rheumatol; 2013 Nov; 32(11):1569-74. PubMed ID: 23877490
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study.
    Nüesch E; Trelle S; Reichenbach S; Rutjes AW; Tschannen B; Altman DG; Egger M; Jüni P
    BMJ; 2010 Jul; 341():c3515. PubMed ID: 20639294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis.
    Reginster JY; Cooper C; Hochberg M; Pelletier JP; Rizzoli R; Kanis J; Abadie E; Maheu E; Brandi ML; Devogelaer JP; Branco J; Herrero-Beaumont G; D'Hooghe P; Bruyère O
    Curr Med Res Opin; 2015 May; 31(5):1041-5. PubMed ID: 25753599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osteoarthritis of the Hip and Knee: Can Antidepressants Help?
    Sonoda K
    Am Fam Physician; 2023 Jun; 107(6):582-583. PubMed ID: 37327156
    [No Abstract]   [Full Text] [Related]  

  • 52. Diacerein. A controversial EU re-evaluation upholds marketing authorisation, unfortunately.
    Prescrire Int; 2015 Apr; 24(159):94. PubMed ID: 25941698
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What is the role of antidepressants for patients with hip and knee osteoarthritis? A Cochrane Review summary with commentary.
    Moretti A
    Int J Rheum Dis; 2023 Dec; 26(12):2551-2554. PubMed ID: 37877139
    [No Abstract]   [Full Text] [Related]  

  • 54. No evidence that drugs reduce progression of osteoarthritis.
    Drug Ther Bull; 2022 Jan; 60(1):4. PubMed ID: 34893499
    [No Abstract]   [Full Text] [Related]  

  • 55. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy.
    Chevalier X; Conrozier T; Richette P
    Arthritis Res Ther; 2011 Aug; 13(4):124. PubMed ID: 21888686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing the management of osteoarthritis-Transitioning evidence-based guidelines into practical guidance for real-world clinical practice.
    Reginster JY; Cooper C
    Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S1-2. PubMed ID: 26806186
    [No Abstract]   [Full Text] [Related]  

  • 57. Current DMOAD options for the treatment of osteoarthritis.
    Yeap SS
    Clin Exp Rheumatol; 2020; 38(4):802. PubMed ID: 32141438
    [No Abstract]   [Full Text] [Related]  

  • 58. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?
    Qvist P; Bay-Jensen AC; Christiansen C; Dam EB; Pastoureau P; Karsdal MA
    Pharmacol Res; 2008 Jul; 58(1):1-7. PubMed ID: 18590824
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies.
    Lim YZ; Wang Y; Estee M; Abidi J; Udaya Kumar M; Hussain SM; Wluka AE; Little CB; Cicuttini FM
    Osteoarthritis Cartilage; 2022 Nov; 30(11):1434-1442. PubMed ID: 35597372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Tale of Confusion From Overlapping Confidence Intervals.
    Mittal N; Bhandari M; Kumbhare D
    Am J Phys Med Rehabil; 2019 Jan; 98(1):81-83. PubMed ID: 30119088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.